Patent classifications
A61K31/473
Catecholamine prodrugs for use in the treatment of parkinson's disease
The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
COMPOUNDS FOR THE TREATMENT OF COVID-19
The present invention relates to compounds that are able to inhibt functional proteins of COVID-19 virus, SARS-Cov-2.
COMPOUNDS FOR THE TREATMENT OF COVID-19
The present invention relates to compounds that are able to inhibt functional proteins of COVID-19 virus, SARS-Cov-2.
NON-COVALENT LOADING OF PLANT PICOVIRUS PARTICLES
A method of non-covalently loading a plant picornavirus is described. The method includes contacting a plant picornavirus in solution with a molar excess of a cargo molecule to load the plant picornavirus with the cargo molecule, and then purifying the loaded plant picornavirus. Examples of cargo molecules include imaging agents, antitumor agents, and antiviral agents. Loaded plant picornaviruses prepared in this manner can be used to delivering cargo molecule to cells.
NON-COVALENT LOADING OF PLANT PICOVIRUS PARTICLES
A method of non-covalently loading a plant picornavirus is described. The method includes contacting a plant picornavirus in solution with a molar excess of a cargo molecule to load the plant picornavirus with the cargo molecule, and then purifying the loaded plant picornavirus. Examples of cargo molecules include imaging agents, antitumor agents, and antiviral agents. Loaded plant picornaviruses prepared in this manner can be used to delivering cargo molecule to cells.
TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS
The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
AZAPODOPHYLLOTOXIN DERIVATIVES AND METHODS OF TREATING LYMPHOMA AND KIDNEY CANCER
Methods of inhibiting the proliferation of a cancer cell, and treating cancer in an individual are provided. Aspects of the subject methods include contacting a cancer cell with an azapodophyllotoxin derivative, where the contacting is effective to inhibit tubulin polymerization and monoglycerol metabolism to inhibit proliferation of cancer in the cell. In certain cases, the cancer cell is a renal cancer cell (RCC) or a lymphoma cell. Aspects of the methods also include administering to a subject an effective amount of an azapodophyllotoxin derivative to treat the subject for cancer, where the cancer is selected from renal cancer and lymphoma. Also provided is a method of monitoring tumor regression in an individual, and methods of identifying a cancer suppressing compound.
AZAPODOPHYLLOTOXIN DERIVATIVES AND METHODS OF TREATING LYMPHOMA AND KIDNEY CANCER
Methods of inhibiting the proliferation of a cancer cell, and treating cancer in an individual are provided. Aspects of the subject methods include contacting a cancer cell with an azapodophyllotoxin derivative, where the contacting is effective to inhibit tubulin polymerization and monoglycerol metabolism to inhibit proliferation of cancer in the cell. In certain cases, the cancer cell is a renal cancer cell (RCC) or a lymphoma cell. Aspects of the methods also include administering to a subject an effective amount of an azapodophyllotoxin derivative to treat the subject for cancer, where the cancer is selected from renal cancer and lymphoma. Also provided is a method of monitoring tumor regression in an individual, and methods of identifying a cancer suppressing compound.
Compositions and methods for treating centrally mediated nausea and vomiting
Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
Compositions and methods for treating centrally mediated nausea and vomiting
Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.